Detection of epileptic activity in presumably normal EEG

Sara Baldini,1,* Francesca Pittau,1,* Gwenaël Birot,2 Vincent Rochas,1 Miralena I. Tomescu,2 Serge Vulliémoz1 and Margitta Seeck1

*These authors contributed equally to this work.

Monitoring epileptic activity in the absence of interictal discharges is a major need given the well-established lack of reliability of patients’ reports of their seizures. Up to now, there are no other tools than reviewing the seizure diary; however, seizures may not be remembered or dismissed voluntarily. In the present study, we set out to determine if EEG voltage maps of epileptogenic activity in individual patients can help to identify disease activity, even if their scalp EEG appears normal. Twenty-five patients with pharmacoresistant focal epilepsy were included. For each patient, 6 min of EEG with spikes (yes-spike) and without visually detectable epileptogenic discharges (no-spike) were selected from long-term monitoring recordings (EEG 31–37 channels). For each patient, we identified typical discharges, calculated their average and the corresponding scalp voltage map (‘spike-map’). We then fitted the spike-map for each patient on their (i) EEG epochs with visible spikes, (ii) epochs without any visible spike and (iii) EEGs of 48 controls. The global explained variance was used to estimate the presence of the spike-maps. The individual spike-map occurred more often in the spike-free EEGs of patients compared to EEGs of healthy controls (P = 0.001). Not surprisingly, this difference was higher if the EEGs contained spikes (P < 0.001). In patients, spike-maps were more frequent per second (P < 0.001) but with a shorter mean duration (P < 0.001) than in controls, for both no-spike and yes-spike EEGs. The amount of spike-maps was unrelated to clinical variables, like epilepsy severity, drug load or vigilance state. Voltage maps of spike activity are present very frequently in the scalp EEG of patients, even in presumably normal EEG. We conclude that spike-maps are a robust and potentially powerful marker to monitor subtle epileptogenic activity.

1 EEG and Epilepsy Unit, Neurology Department, University Hospitals and Faculty of Medicine of Geneva, Geneva, Switzerland
2 Functional Brain Mapping Laboratory, Department of Fundamental Neurosciences, University of Geneva, Geneva, Switzerland

Correspondence to: Margitta Seeck, MD, EEG and Epilepsy Unit, Department of Clinical Neurosciences, University Hospitals and Faculty of Medicine of Geneva, Geneva, Switzerland
E-mail: Margitta.seeck@hcuge.ch

Keywords: interictal spikes; scalp voltage maps; pharmacoresistant epilepsy; EEG

Abbreviations: CBZ = carbamazepine; CLB = clobazam; CNZ = clonazepam; DNET = dysembryoplastic neuroepithelial tumour; FCD = focal cortical dysplasia; GEV = global explained variance; GFP = global field power; HS = hippocampus sclerosis; IEDs = interictal epileptiform discharges; LC = left-central; LCP = left-central-parietal; LCS = lacosamide; LEV = levetiracetam; LF = left-frontal; LPO = left-parietal-occipital; LT = left-temporal; LTG = lamotrigine; OXC = oxcarbazepine; PNES = psychogenic non-epileptic epileptic seizure; RF = right-frontal; RFN = rufinamide; ROF = right-occipital-frontal; RT = right-temporal; sGEV = standardized global explained variance; TPM = topiramate; VPA = valproate; ZNS = zonisamide

Received July 9, 2019. Revised April 27, 2020. Accepted May 15, 2020
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Epilepsy is one of the most frequent chronic neurological disorders, with a prevalence of 0.5–1% in the general population (Sander, 2003). A challenging problem in managing patients is to determine if their seizures are, in fact, controlled by the prescribed medical treatment given the unreliability of patient self-report and the absence of devices that reliably monitor seizure frequency (Cook et al., 2013). To close this gap, an objective marker of ongoing epileptogenic activity is needed. Ideally, such a marker would be based on EEG well established that the detection of interictal epileptic discharges in scalp EEG (comprising spike-waves, polyspike-waves or spikes; here-under called spikes) has a low sensitivity. Even in patients with very active epilepsy, a 20–30 min standard EEG (as it is usually practiced), may contain no spikes and thus be incorrectly reported as normal, i.e., making it an imperfect marker of active epileptogenicity in the individual patient. In clinical practice, EEG spikes are defined as graph elements with specific characteristics and morphological features, usually based on visual analysis of EEG curves (Gibbs et al., 2002). However, in addition to this conventional approach, spikes can be also characterized by whole-scalp topographic maps specific to the epileptogenic focus localization (Scherg and Ebersole, 1993; Koenig et al., 2002). Voltage maps have been proposed as a possible biomarker of different neuropsychiatric diseases (Ebersole and Wade, 1990; Lopes da Silva, 1990). Indeed, spike-specific voltage maps seem to be present even if no-spike-graphic element is visible in the EEG curves. In a combined EEG-functional magnetic resonance imaging study using caps with 32–94 electrodes, Grouiller et al. (2011) showed that specific voltage maps of epileptogenic discharges—‘spike-maps’—have haemodynamic correlates that are concordant with the epileptic focus (Grouiller et al., 2011). They used long-term EEG recording results of patients with focal epilepsy to define the topographic voltage map of the spikes and then fitted the patient’s map to the ongoing EEG recorded in the scanner (without any visually detectable spikes). The time course of the spike-map correlated with the hemodynamic response function and showed blood oxygenation level-dependent changes in the epileptic zone, as validated by the post-operative result. This study strongly suggests the presence of spike-specific maps in the scalp EEG even in the absence of visible spikes, which could be a marker of ongoing activity in the epileptogenic focus area.

In the present study, we investigated whether spike-maps, obtained in a clinical setting (long-term video-EEG recording), can be detected in the EEG of patients with known active uncontrolled focal epilepsy but who showed no visible spikes during the EEG epochs. We were interested in evaluating the potential of the individual spike-maps as a marker to reveal visually undetected epileptic activity, given the low clinical yield of visual search for discharges in scalp EEG. To this end, we compared the frequency of spike-maps during periods of visually ‘normal’ EEG epochs versus epochs containing visible epileptogenic discharges in the same patient and to EEG epochs of a healthy control group.

Materials and methods

Subjects and recordings

We retrospectively analysed 25 patients with pharmacoresistant focal epilepsy who had been hospitalized for presurgical evaluation in 2013–15 at our Epilepsy Unit at the University Hospitals of Geneva. Inclusion criteria were: focal epilepsy, unifocal interictal epileptiform discharges (IEDs), artefact-free EEG obtained with at least 31 electrodes, >24 h since the last seizure. Exclusion criteria were: multifocal or generalized epilepsy, multifocal interictal discharges. Spikes were defined as transient events, distinguishable from the background activity with at least 2× higher amplitude than the background or...
with an evocative morphology, including a peak at conventional screen display and duration of 20–70 ms. A similar definition was used for sharp waves, but the duration could be up to 200 ms. For each patient, we selected two periods of 6 min, i.e., EEG with spikes (yes-spike-condition) and without any detectable spike during wakeful rest (no-spike-condition). The following electrodes were placed according to the 10–10 system: Fp1, Fp2, F7, F8, F3, F4, Fz, T3, T4, C3, Cz, C4, T5, T6, P3, Pz, P4, O1, O2, FC1, FC2, FC5, FC6, CP1, CP2, CP5, CP6, TP9, TP10, F9/10, T9/10 and P9/10; ref: Fcz. Impedence was kept at <5 kΩ. EEG was recorded with a sampling rate at 256 Hz. Six minutes of wakeful resting-state EEG from 48 healthy subjects [24 female, age (mean ± SD) 32.9 ± 9.08 years] were also obtained and served as controls.

**EEG data pre-processing**

The EEG was band-pass filtered offline between 1 and 40 Hz. Independent component analysis was applied to remove cardiac and oculomotor artefacts, based on the time course, the topography, and the waveform of the independent component analysis component (Jung et al., 2000). Electrodes affected by artefacts were interpolated using a 3D spherical spline (Perrin et al., 1989); the data were downsampled to 128 Hz and then recomputed to common average-reference. Voltage maps were computed at every sampling point. When the EEG-values at each sampling point and for each electrode of each electrode and time point are plotted across the scalp, a voltage map emerges. In order to visualize voltage maps, positive and negative values are computed and colour-coded. As established in the literature, positive values are red, negative amplitude values are blue and 0-values are white. Voltage maps are relatively robust regarding the amplitude of the signal, i.e., a large spike or subtle invisible spike lead to the same voltage map.

In order to improve the signal-to-noise ratio, only the data at the time points of the local maxima of the global field power (GFP) were submitted to further analysis (Britz et al., 2010). The GFP is a scalar measure of the strength of the scalp potential field and is calculated as the standard deviation of all electrodes at a given time point (Michel et al., 1993; Lehmann et al., 1998; Brunet et al., 2011). Thus, GFP maxima reflect maximal synchronized neuronal activity (Skrandies, 1990). Voltage maps tend to be stable around the maxima, but do not carry any information on normal or pathological content. Any EEG can be described by a sequence of GFP maxima, i.e., voltage maps representing physiological brain activity like resting states as well as epileptogenic activity (spike-map). For the purpose of the study, we concentrate our analysis on the spike-maps (Fig. 1, orange boxes).

**Analysis**

For each patient, we determined the individual spike-specific EEG voltage map using the averaged spikes typical for that patient. A board-certified EEG-expert (F.P., S.V., M.S.) marked the peak of an average of 15 spikes from the 6-min segment of the EEG with spikes. After band-pass filtering (1–40 Hz), the spikes were averaged aligned to the peak and the average EEG voltage map at the peak of GFP was considered as the ‘spike-map’ (Grouiller et al., 2011). We fitted the spike-map on the GFP local maxima of (i) EEG of a patient with visible spikes (yes-spike-condition), (ii) EEG of the same patient without any visible spike (no-spike-condition) and (iii) EEGs of the 48 controls (Fig. 1). The spatial correlation between the spike-map and the recorded EEG at each time point of the two EEG-segments was computed (Michel and Murray, 2012). The presence of the epileptic map on such EEGs was quantified by the global explained variance (GEV) (Murray et al., 2008). The GEV is the temporal mean of the absolute value of the spatial correlation weighted by the GFP. We also computed, among the GFP peaks of the entire EEG, the frequency of occurrence (how many times a voltage map is recurring per second) and mean duration (averaged amount of time, in ms, that a voltage map was continuously present) of the spike-map.

The EEG data pre-processing and analyses were performed with the freely available Cartool software package (release 3.51) (Brunet et al., 2011).

**Statistical analysis**

We assessed whether GEV, frequency and mean duration obtained from the patient’s EEG, with or without a spike, were statistically different from those of the control group composed of the 48 individuals. We performed the normality test (one-sample Kolmogorov–Smirnov test; \( \alpha = 0.05 \)) on the variables distribution for patients and controls, which confirmed normal distributions in all fitting combinations for each epileptic map. We then standardized GEV, frequency and mean duration for each patient by calculating the Z-score, i.e., subtracting the mean values of the controls from the patient’s value and then dividing the difference by the standard deviation of the controls. We thereby obtained standardized values of the GEV (sGEV), frequency and mean duration for each patient allowing comparison across all patients. This standardization allowed for statistical testing at the group level by comparing the variables distributions of the patient group (\( N = 25 \)) with the reference distribution of the control group. The \( P \)-value is given by \( 1 - (Z - \alpha) \), where standard normal cumulative distribution function is the cumulative distribution function of the standard normal distribution.

The Pearson’s correlation coefficient was computed in order to assess whether GEV values, obtained in the EEG
without spikes, were correlated to the following clinical variables: disease duration, age of onset and frequency of seizures per week. In addition, independent samples t-tests were performed to compare the GEV values between the following nominal variables: (i) lack of contact during seizure or not; (ii) presence or absence of psychiatric impairments; (iii) presence or absence of a structural lesion; (iv) presence or absence of tonic-clonic seizures and (v) number of antiepileptic drugs at the moment of hospitalization.

Even though the EEG was recorded during wakefulness, subtle background slowing indicative of light sleep was not excluded. Since spikes, and maybe also spike-maps, tend to occur more often during light sleep, we filtered each EEG in the low (1–7 Hz) and in the high (8–40 Hz) frequency band and performed the fitting of the individual spike-maps, separately, in these two filtered files. We compared the GEV values, respectively, for the no-spike and yes-spike condition, by a paired samples t-test.

Finally, we set out to determine if spike-maps were associated with subtle epileptogenic discharges, which escaped visual analysis. Topographic correlation between the spike-map and the map of each time frame of the raw no-spike-condition EEG was realized with the freely available Cartool software package (release 3.51) (Brunet et al., 2011). Only correlations \( r \geq 0.9 \) were considered ‘high’ and taken for the analysis. We selected and averaged the EEG from –500 ms to +500 ms around the time frame of spike-map (i.e. EEG highly suggestive of the presence of spike-map) to look for the presence of subtle spikes.

Statistical analyses were run on SPSS (version 20, IBM Corporation, Armonk, NY, USA). A value of \( P < 0.05 \) as considered statistically significant.

Data availability

Raw data were gathered at the University Hospitals of Geneva, Epilepsy Unit. Derived data supporting the findings of this study are available from the corresponding author on request.

Results

The clinical characteristics of the 25 patients are summarized in Table 1 [11 females, age (mean ± SD) 31 ± 3 years; range 11–58 years]. Average disease duration was 17 ± 3 years (mean ± SD; range 1–49 years). Magnetic resonance imaging (MRI) findings were heterogeneous; most patients had normal MRI or focal cortical dysplasia. Localization of epilepsy was noted in the...
Epileptic activity in unrevealing EEG

Table 1: Clinical characteristics of the patient cohort and antiepileptic drug treatment on admission

| Patients | Age at evaluation/sex/age at onset | Duration of disease | MRI | Epilepsy localization | Generalized tonic-clonic seizures | Average seizure frequency | Psychiatric comorbidity | AED1 | AED2 | AED3 | AED4 |
|----------|-------------------------------------|---------------------|-----|-----------------------|-----------------------------------|--------------------------|------------------------|------|------|------|------|
| 1        | 43/F/35                             | 8                   | N   | RT                    | Yes                               | 1/day                    | Anxiety                | LTG 300| ZNS 50| VPA 1000 |
| 2        | 9/M/1                               | 8                   | N   | LC                    | Yes                               | 2/weeks                  | No                      | LTG 20| VPA 600| TPM 25  |
| 3        | 26/F/13                             | 13                  | N   | LT                    | No                                | 1/3 weeks                | No                      | LTG 600| LEV 2000 |
| 4        | 41/M/33                             | 8                   | N   | RT                    | Yes                               | 1/month                 | No                      | VPA2000 | CBZ 400 |
| 5        | 16/M/8                              | 8                   | N   | RF                    | Yes                               | 1x/year                 | No                      | LTG 400| LEV 2000 |
| 6        | 38/B/24                             | 14                  | N   | LT                    | Yes                               | 4/month                 | No                      | LCS 400 | CBZ 400 |
| 7        | 52/F/22                             | 30                  | N   | RT                    | No                                | 5/week                  | No                      | OXC 900 | TPHM 150 |
| 8        | 24/F/12                             | 12                  | N   | LT                    | Yes                               | 1/month                 | No                      | VPA 1600 | |
| 9        | 26/M/18                             | 8                   | HS  | LT                    | Yes                               | 1/week                  | No                      | LEV 1000 | LTG 600 |
| 10       | 51/M/16                             | 35                  | HS  | LT                    | Yes                               | 10/month                | PNES                   | VPA 1600 | |
| 11       | 42/F/17                             | 25                  | HS  | LT                    | Yes                               | 1/week                  | Depression             | LTG 400 | PRM 750 |
| 12       | 20/F/9                              | 11                  | FCD | ROF                   | No                                | 5/day                   | No                      | CBZ 800 | CLB 20 | LTG 400 |
| 13       | 41/M/24                             | 17                  | FCD | RT                    | No                                | 15/month                | No                      | VPA 1000 | LTG 150 | CBZ 1200 | PER 10 |
| 14       | 31/F/7                              | 24                  | FCD | LF                    | No                                | 2/day                   | No                      | CLB 30 | RNF 2400 | LEV 2000 | PB 300 |
| 15       | 55/F/6                              | 49                  | FCD | RF                    | No                                | 3/day                   | No                      | CEZ 400 | LEV 2000 |
| 16       | 35/M/25                             | 10                  | FCD | LF                    | Yes                               | 2/week                  | Narcissistic personality traits | CEZ 1200 | VPA 1000 |
| 17       | 12/F/1                             | 11                  | FCD | LC                    | No                                | 3/week                  | No                      | OXC 1050 | VPA 750 | CNZ 0.5 |
| 18       | 23/M/12                             | 11                  | FCD | RT                    | Yes                               | 8/year                  | No                      | TPM 300 | LTG 300 | LEV 2000 |
| 19       | 18/F/11                             | 7                   | FCD | LPO                   | Yes                               | 2/day                   | No                      | CEZ 10000 | ZNS 300 |
| 20       | 50/M/1                              | 49                  | FCD | LF                    | Yes                               | 3/week                  | Depression             | LTG 200 | LEV 2000 | CLB 10 | LCS 400 |
| 21       | 13/M/8                              | 5                   | FCD | RF                    | No                                | 2/day                   | No                      | CBZ 500 | LTG 100 |
| 22       | 15/M/11                             | 14                  | N   | LPO                   | Yes                               | 1/week                  | No                      | LTG 200 | VPA 1800 | CBZ 800 |
| 23       | 15/F/13                             | 2                   | DNET| LT                    | No                                | 3/day                   | No                      | LTG 100 | LEV 1000 |
| 24       | 15/M/9                              | 6                   | Haemorrhagic lesion   | LCPC                               | Yes                               | 3/month                 | No                      | LTG 175 | LEV 1000 | VPA 750 |
| 25       | 40/M/2                              | 38                  | Post-traumatic lesion | RF                                 | Yes                               | 9/year                  | Depression, anxiety     | CBZ 1200 | CNZ 6 |

CBZ = carbamazepine; CLB = clobazam; CNZ = clonazepam; DNET = dysembryoplastic neuroepithelial tumour; FCD = focal cortical dysplasia; HS = hippocampus sclerosis; LC = left-central; LCP = left-central-parietal; LCS = lacunosum; LEV = levetiracetam; LF = left-frontal; LPO = left-parieto-occipital; LT = left-temporal; LTG = lamotrigine; N = normal; OXC = oxcarbazepine; PNES = psychogenic non-epileptic seizure; PRM = primidone; PER = perampanel; PB = phenobarbital; RF = right-frontal; RNF = rufinamide; ROF = right-occipital-frontal; RT = right-temporal; TPHM = topiramate; VPA = valproate; ZNS = zonisamide.

All number refers to dosages in milligram.

In the EEG with visible spikes, the GEV of 8–40 Hz was independent of the predominant background frequencies. In these two patients (Subjects 8 and 19) the GEV value was no correlation with the number of drugs being taken or presence or absence of psychiatric impairments (t = 0.986), or presence or absence of a structural lesion (t = 1.494, df = 23, P = 0.149), presence or absence of psychotic impairments (t = −0.372, df = 23, P = 0.713). There was no correlation with the number of drugs being taken by the patient at the moment of hospitalization (r = 0.029, P = 0.269).

Analysis on the filtered EEG showed that the presence of the spike-map in patients compared to controls is independent of a specific frequency band (Table 2). Among patients, there were no differences between the 1–7 Hz band and the 8–40 Hz band (t = −0.485, df = 24, P = 0.632) in the EEG without visible spikes, suggesting that the presence of spike-map in the no-spike-condition is independent of the predominant background frequencies. In the EEG with visible spikes, the GEV of 8–40 Hz was shorter (no-spike: t = −12.860, df = 24, P < 0.001; yes-spike: t = −14.993, df = 24, P < 0.001) (Fig. 4).
significantly higher when compared to the 1–7 Hz filtered EEG ($t = -3.506, df = 24, P < 0.001$), due to the presence of spikes, which are by definition characterized by higher frequencies. In order to confirm that there was no discernible epileptogenic activity in the scalp EEG itself and verify that there were no overlooked small-amplitude visible spikes, we averaged the time frames at the moment of maximal correlation with the spike-map in the no-spike-condition condition. We did not see any graph elements resembling a spike in any of the patients (Fig. 5).

**Discussion**

To the best of our knowledge, this is the first study exploring the use of epileptogenic discharge-related voltage topographic maps (‘spike-maps’), computed from scalp EEG, as a marker of epileptogenic activity in patients with known focal epilepsy. These maps were found significantly more often in patients compared to controls, independent of the presence of visible epileptogenic discharges. Spike-maps therefore appear to have the potential to correctly identify patients with active epilepsy even in recordings with normal-appearing scalp EEGs, provided that their EEG-focus was determined in a previous work-up (e.g. with a sleep EEG). Patients with chronic focal epilepsy are particularly difficult to monitor with respect to drug response, given that they are often amnesic for their seizures, in particular if seizures involve the left-temporal lobe (Lux *et al.*, 2002). Studies with implanted devices found major discrepancies between reported and actually occurring seizures (Cook *et al.*, 2013). In contrast, in
patients with generalized epilepsy, provocation manoeuvres, like hyperventilation or photic stimulation, or morning EEGs allow determining relatively easily with visual analysis if the epilepsy is controlled with reasonable certainty (Fittipaldi et al., 2001; Labate et al., 2007).

The results of this study are also in line with our previous EEG-functional magnetic resonance imaging findings which showed that presumably negative EEG from surgical candidates obtained inside the magnetic resonance imaging scanner contains spike-map that can be used to identify the epileptogenic focus reflected by corresponding regions of blood oxygenation level-dependent changes (Grouiller et al., 2011). In 78% of the patients, the localization was correct using very stringent criteria, i.e., complete seizure control after resection of the so-identified area. In a more recent study, we could also show the existence of the patient’s individual epileptic network, detectable as haemodynamic map in the functional magnetic resonance imaging, which is largely preserved even when the contribution of spikes detected on scalp EEG is removed (Iannotti et al., 2016).

Visible spike activity represents most likely only the ‘tip of the iceberg’ of the pathological focal epileptic activity (Alarcon et al., 1994; Tao et al., 2007; von Ellenrieder et al., 2014). Spikes may remain spatially limited in deep structures and not recruit the necessary 4–6 cm³ of the cortex to be visible (Tao et al., 2007). Nevertheless, their presence is strong and frequent enough to shape the scalp EEG using the whole-scalp topography even when they are not discernable using conventional visual inspection methods. Indeed, a study (Koessler et al., 2015) on seven patients recorded with simultaneous scalp and intracranial EEG showed that deep cerebral sources (i.e. mesial temporal) are not visible on the scalp at the single sweep level, due to too low signal-to-noise ratio, but contribute to the topography in the scalp EEG. Our finding strengthens this assumption: when we averaged the EEG at the moment of maximal correlation of the spike-map in the no-spike-condition condition, we found no clearly visible abnormality in the EEG traces, neither low amplitude discharges nor focal slow waves, both in single sweeps and after averaging.

There is still controversy about the relationship between the appearance of IEDs and seizure risk. A review based on animal studies suggested a rather protective effect (De Curtis and Avanzini, 2001). In patients, it appears that a higher IED frequency correlates with a higher seizure likelihood. Baud et al. (2018) analysed data from intracranial recordings in 37 patients who received a closed-loop implantable brain stimulator, allowing hourly calculated IEDs and seizures over a median of 2.3 years. Seizures occurred preferentially during periods of high IED load, indicating that IEDs carry prognostic information on seizure probability. While the correlation is not absolute, it matches the clinical impression that seizure relapses in focal epilepsy are often associated with an increase of pathological discharges in the scalp EEG.

In two cases (8%), the spike-map was more prevalent in the EEG of healthy controls than in the no-spike-
Condition EEG of the patients. In both cases, the maps resembled strongly physiological microstates, i.e., maps that correlate with blood oxygenation level-dependent signal changes labelled as auditory (Patient 8) and visual resting-state networks (Patient 19, Fig. 5; Britz et al., 2010). In fact, in the scalp EEG of healthy subjects, 4–11 resting states were identified, which can be also retrieved in resting functional magnetic resonance imaging (Britz et al., 2010; Musso et al., 2010).

In the current study, we were interested to determine if spike-related voltage maps are specific enough to be used as a marker of epileptic activity. The comparison with
healthy control allowed determining if spike-maps were unique for patients or if they were also found in the EEGs of non-epileptic subjects. If spike-maps occurred equally often in both groups, they would be useless as a marker of epileptogenic activity because they would occur also as part of normal brain activity. In all but two subjects (92%), individual spike-maps were identified which were clearly different from physiological maps in the control group. Regarding patients with spike-maps mimicking physiological maps, future studies will show if more electrodes (e.g. 64 electrodes) allow better differentiation from controls.

The results indicate the presence of epileptogenic activity even if the EEG is unrevealing. While this has been shown with the help of functional magnetic resonance imaging or intracranial recordings, we now present evidence that hidden epileptogenic activity can be reliably recognized in scalp EEG. Spike-maps were more frequent but shorter than in controls. These findings corroborate clinical observations that epileptogenic activity is frequent but short and sudden appearance leading to the well-described interictal cognitive deficits.

The number and type of antiepileptic drugs taken by our cohort of patients were not a contributing factor to our findings. However, we only examined patients with epilepsy who were candidates for epilepsy surgery. By definition, their epilepsy did not respond to at least two drugs. These patients have seizures under full drug regimen, i.e., chronic epileptogenicity can be readily assumed, with the moderate impact of partial drug withdrawal.

While we used only wake EEG, brief light sleep might have occurred increasing the likelihood of subtle or visible epileptogenic activity. However, in the no-spike-condition, there were no differences in the presence of spike-maps retrieved between EEGs containing mainly lower or higher frequencies.

It is of note that the presence of spike-maps was not correlated with clinical variables of severity such as duration of disease, presence of a structural lesion or history of generalized tonic-clonic seizures. With the inherent limitations of a small study, our results indicate that spike-maps are a robust marker of epileptogenic activity and relatively independent from disease evolution or vigilance state.

Studies with larger patient populations will help to establish a sensitivity, specificity, positive and negative predictive values of spike-maps as a marker of epileptogenic activity in patients with focal epilepsy. Cut-off values of good versus deficient epilepsy control or epileptic versus non-epileptic conditions will also need to be established. Further studies will help to determine if our findings extend also to other clinical scenarios, for example, the utility of spike-maps as a marker of long-lasting drug response after the first seizure or for compliance monitoring. Finally, the question of a universal pathological map or a repertoire of maps in patients as part of their initial work-up after a suspicious event is of major ongoing interest. While it may not be related to the presence of a particular spike-map, changes in the relative frequency or duration of physiological maps could provide a hint for the presence of a previously undetected epilepsy disorder.

**Funding**

The study was supported by the Swiss National Science Foundation (169198, 163398, 192749, Sinergia CRS115-180365 and 170873) and Fondation Privé HUG No RC1-23.

**Competing interests**

M.S. and S.V. have shares in Epilog; M.S. received speakers’ fees from EGI-Philipps and Desitin. The other authors report no disclosures.

**References**

Alarcon G, Guy C, Binnie C, Walker S, Elwes R, Polkey C. Intracerebral propagation of interictal activity in partial epilepsy: implications for source localisation. J Neurol Neurosurg Psychiatry 1994; 57: 435–49.

Baud M, Kleen J, Mirro E, Andrechak J, King-Stephens D, Chang E, et al. Multi-day rhythms modulate seizure risk in epilepsy. Nat Commun 2018; 9: 88.

Briz J, Van De Ville D, Michel CM. BOLD correlates of EEG topography reveal rapid resting-state network dynamics. Neuroimage 2010; 52: 1162–70.

Brunet D, Murray MM, Michel CM. Spatiotemporal analysis of multichannel EEG: CARTOOL. Comput Intell Neurosci 2011; 2011: 1–15.

Cook MJ, O’Brien TJ, Berkovic SF, Murphy M, Morokoff A, Fabinyi G, et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol 2013; 12: 563–71.

De Curtis M, Avanzini G. Intercital spikes in focal epileptogenesis. Prog Neurobiol 2001; 63: 541–67.

Ebersole J, Wade P. Spike voltage topography and equivalent dipole localization in complex partial epilepsy. Brain Topogr 1990; 3: 21–34.

von Ellenrieder N, Beltrachini L, Perucca P, Gotman J. Size of cortical generators of epileptic interictal events and visibility on scalp EEG. Neuroimage 2014; 94: 47–54.

Fittipaldi F, Currà A, Fusco L, Ruggieri S, Manfredi M. EEG discharges on awakening: a marker of idiopathic generalized epilepsy. Neurology 2001; 56: 123–6.

Gibbs FA, Gibbs EL, Lennox WG. Epilepsy: a paroxysmal cerebral dysrhythmia. Epilepsia Behav 2002; 3: 395–401.

Grouiller F, Thornton RC, Groening K, Spinelli L, Duncan JS, Schaller K, et al. With or without spikes: localization of focal electrocorticography and functional. Brain 2011; 134: 2867–86.

Iannotti GR, Grouiller F, Centeno M, Carmichael DW, Abela E, Wiest R, et al. Epileptic networks are strongly connected with and without the effects of interictal discharges. Epilepsia 2016: 1086–1096.

Jung T-P, Makeig S, Lee T-W, McKeown MJ, Brown G, Bell AJ, et al. Independent component analysis of biomedical signals. Int Workshop on Independent Component Analysis and Signal Separation 2000: 633–644.

Koenig T, Prichet L, Lehmann D, Sosa PV, Bracker E, Kleinlogel H, et al. Millisecond by millisecond, year by year: normative EEG microstates and developmental stages. Neuroimage 2002; 16: 41–8.
Koessler L, Cecchin T, Colnat-Coulbois S, Vignal J, Jonas J, Vespignani H, et al. Catching the invisible: mesial temporal source contribution to simultaneous EEG and SEEG recordings. Brain Topogr 2015; 28: 5–20.

Labate A, Ambrosio R, Gambardella A, Sturniolo M, Pucci F, Quattrone A. Usefulness of a morning routine EEG recording in patients with juvenile myoclonic epilepsy. Epilepsy Res 2007; 77: 17–21.

Lehmann D, Strik WK, Henggeler B, Koenig T, Koukkou M. Brain electric microstates and momentary conscious mind states as building blocks of spontaneous thinking: I. Visual imagery and abstract thoughts. Int J Psychophysiol 1998; 29: 1–11.

Lopes da Silva FH. A critical review of clinical applications of topographic mapping of brain potentials. J Clin Neurophysiol 1990; 7: 535–51.

Lux S, Kurthen M, Helmsdeder C, Hartje W, Reuber M, Elger C. The localizing value of ictal consciousness and its constituent functions: a video-EEG study in patients with focal epilepsy. Brain 2002; 125: 2691–8.

Michel CM, Brandeis D, Skrandies W, Pascual R, Strik WK, Dierks T, et al. Global field power: a ‘time-honoured’ index for EEG/EP map analysis. Int J Psychophysiol 1993; 13: 1–5.

Michel CM, Murray MM. Towards the utilization of EEG as a brain imaging tool. Neuroimage 2012; 61: 371–85.

Murray MM, Brunet D, Michel CM. Topographic ERP analyses: a step-by-step tutorial review. Brain Topogr 2008; 20: 249–64.

Musso F, Brinkmeyer J, Mobascher A, Warbrick T, Winterer G. Spontaneous brain activity and EEG microstates. A novel EEG/MRI analysis approach to explore resting-state networks. Neuroimage 2010; 52: 1149–61.

Perrin F, Pernier J, Bertrand O, Echallier JF. Spherical splines for scalp potential and current density mapping. Electroencephalogr Clin Neurophysiol 1989; 72: 184–7.

Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 16: 165–70.

Scherg M, Ebersole J. Models of brain sources. Brain Topogr 1993; 5: 419–23.

Skrandies W. Global field power and topographic similarity. Brain Topogr 1990; 3: 137–41.

Tao J, Baldwin M, Hawes-Ebersole S, Ebersole J. Cortical substrates of scalp EEG epileptiform discharges. J Clin Neurophysiol 2007; 24: 96–100.